Navigation Links
UC Davis Researchers Find How Viral Infection Disrupts Neural Development in Offspring, Increasing Risk of Autism
Date:9/19/2013

Sacramento, CA (PRWEB) September 19, 2013

Activating a mother’s immune system during her pregnancy disrupts the development of neural cells in the brain of her offspring and damages the cells' ability to transmit signals and communicate with one another, researchers with the UC Davis Center for Neuroscience and Department of Neurology have found. They said the finding suggests how maternal viral infection might increase the risk of having a child with autism spectrum disorder or schizophrenia.

The research, “MHCI Requires MEF2 Transcription Factors to Negatively Regulate Synapse Density during Development and in Disease,” is published in the Journal of Neuroscience.

The study’s senior author is Kimberley McAllister, professor in the Center for Neuroscience with appointments in the departments of Neurology and Neurobiology, Physiology and Behavior, and a researcher with the UC Davis MIND Institute.

“This is the first evidence that neurons in the developing brain of newborn offspring are altered by maternal immune activation,” McAllister said. “Until now, very little has been known about how maternal immune activation leads to autism spectrum disorder and schizophrenia-like pathophysiology and behaviors in the offspring.”

The study was conducted in mice and rats and compared the brains of the offspring of rodents whose immune systems had been activated and those of animals whose immune systems had not been activated. The pups of animals that were exposed to viral infection had much higher brain levels of immune molecules known as the major histocompatibility complex I (MHCI) molecules.

“This is the first evidence that MHCI levels on the surface of young cortical neurons in offspring are altered by maternal immune activation,” McAllister said.

The researchers found that the high MHCI levels impaired the ability of the neurons from the newborn mice’s brains to form synapses, the tiny gaps separating brain cells through which signals are transmitted. Earlier research has suggested that ASD and schizophrenia may be caused by changes in the development of connections in the brain, especially the cerebral cortex.

The researchers experimentally reduced MHCI to normal levels in neurons from offspring following maternal immune activation.

“Remarkably, synapse density returned to normal levels in those neurons,” McAllister said.

“These results indicate that maternal immune activation does indeed alter connectivity during prenatal development, causing a profound deficit in the ability of cortical neurons to form synapses that is caused by changes in levels of MHCI on the neurons,” she said.

MHCI did not work alone to limit the development of synapses. In a series of experiments, the UC Davis researchers determined that MHCI interacted with calcineurin and myocyte enhancer factor-2 (Mef2), a protein that is a critical determinant of neuronal specialization.

MHCI, calcineurin and Mef2 form a biological signaling pathway that had not been previously identified. McAllister’s team showed that in the offspring of the maternal immune activation mothers, this novel signaling pathway was much more active than it was in the offspring of non-MIA animals.

“This finding provides a potential mechanism linking maternal immune activation to disease-linked behaviors,” McAllister said.

It also is a mechanism that may help McAllister and other scientists to develop diagnostic tests and eventually therapies to improve the lives of individuals with these neurodevelopmental disorders.

Other study authors are Bradford M. Elmer, Myka L. Estes and Stephanie L. Barrow, all of UC Davis.

The research was supported the National Institute of Neurological Disorders and Stroke (R01 NS060125), the UC Davis Research Investments in Science and Engineering Program, Dennis Weatherstone Predoctoral Fellowships (No. 6339 and No. 7825) and the National Center for Advancing Translational Sciences (UL1 TR 000002 and linked award TL1 TR 000133).

The UC Davis School of Medicine is among the nation's leading medical schools, recognized for its research and primary-care programs. The school offers fully accredited master's degree programs in public health and in informatics, and its combined M.D.-Ph.D. program is training the next generation of physician-scientists to conduct high-impact research and translate discoveries into better clinical care. Along with being a recognized leader in medical research, the school is committed to serving underserved communities and advancing rural health. For more information, visit UC Davis School of Medicine at http://medschool.ucdavis.edu.

Read the full story at http://www.prweb.com/releases/2013/9/prweb11144094.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Novel Vaccine Approach to Human Cytomegalovirus Found Effective Says UC Davis Study
2. UC Davis study applies timely cost-effectiveness analysis to state breast cancer screening program
3. CareClix Provides Telemedicine Services to Leading Provider of Warehouse and Shipping Services, Davis Storage of Danville, Virginia
4. UC Davis Children's Hospital Saves the Life of 14-year-old Bishop, Calif. Teen Infected with Hantavirus
5. UC Davis Study Identifies Better Blood Glucose Monitor for Burn Care
6. UC Davis Team "Spikes" Stem Cells to Generate Myelin
7. UC Davis Develops New Strategy Tests for Dangerous Stage of Tuberculosis in Asia
8. UC Davis Children's Hospital Study Finds Telemedicine Consultations Significantly Improve Pediatric Care in Rural Emergency Rooms
9. UC Davis "Lab on a Chip" Measures Heart Disease Risk
10. Davis Hospital and Medical Center is First Hospital in Utah to Offer New CelluTome™ System for Skin Grafting
11. Actors, Models & Talent for Christ Grad, Charles Michael Davis, Stars in Grey’s Anatomy, Another Stateside (post-production), and New TV Series The Originals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... QualDerm Partners , a ... today announced Cumberland Skin Surgery and Dermatology has joined the company ... in both Hermitage and Lebanon, Tennessee, provides comprehensive general dermatology and skin cancer ...
(Date:8/16/2017)... Island, NY (PRWEB) , ... August 16, 2017 , ... ... with IV starts and blood draws. By broadly deploying AccuVein devices, Maury Regional Medical ... takes much of the guesswork out of a needle stick and more importantly, helps ...
(Date:8/16/2017)... ... August 16, 2017 , ... Paul Vitenas, MD, FACS , is honored ... The annual list identifies the nation’s top physicians, in a variety of specialties. This ... the top of Castle Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted ...
(Date:8/16/2017)... ... , ... A global leader in the treatment of clubfoot, CURE International ... states—bringing the country one step closer to eliminating clubfoot as a lifelong disability by ... track to enroll 10,000 children in the clubfoot treatment program in this year alone. ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... states: “Drying the endoscope after every reprocessing cycle, both between patient procedures and ... and nosocomial infections. Drying is as important to the prevention of disease transmission ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
(Date:7/28/2017)... 2017 EnvoyHealth, a Diplomat company, has partnered with ... CleverCap LITE, a technology designed to improve patient medication ... health technology solutions and services that help track and ... CleverCap LITE offers medication monitoring and control for ... Records date and time ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals Company, ... our clinical trial evaluating Altemia TM , an oral ... and Sickle Cell Disease (SCD). The SCOT Trial, is ... efficacy and safety of Altemia TM in pediatric ... under US IND 125274. ...
Breaking Medicine Technology: